{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T10:30:50Z","timestamp":1793442650049,"version":"4.5.0"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T00:00:00Z","timestamp":1785628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Health Policy OPEN"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.hpopen.2026.100180","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:38:36Z","timestamp":1786034316000},"page":"100180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The impact of the United States most favored nation policies on prices of branded medicines and research and development"],"prefix":"10.1016","volume":"11","author":[{"given":"David","family":"Epstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hpopen.2026.100180_bb0005","series-title":"Speech before first international colloquium on generic medicine","article-title":"Colloquium on generic medicine","author":"McClellan","year":"2003"},{"issue":"2","key":"10.1016\/j.hpopen.2026.100180_bb0010","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1257\/jep.20241418","article-title":"Lessons for the United States from pharmaceutical regulation abroad","volume":"39","author":"Kyle","year":"2025","journal-title":"J Econ Perspect"},{"key":"10.1016\/j.hpopen.2026.100180_bb0015","unstructured":"Edwards J. Most Favored nation (MFN) drug pricing proposal reintroduced in 2025. Medicare Nationwide 2025, September 18th. [Online]. Accessed 10\/08\/2026 Available https:\/\/medicarenationwide.com\/most-favored-nation-mfn-drug-pricing-2025\/#:~:text=The Most Favored Nation %28MFN%29 drug pricing proposal%2C,high prescription costs and improve affordability for seniors."},{"issue":"1","key":"10.1016\/j.hpopen.2026.100180_bb0020","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/jama.2024.22582","article-title":"Drug prices negotiated by Medicare vs US net prices and prices in other countries","volume":"333","author":"Wouters","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.hpopen.2026.100180_bb0025","series-title":"Executive order 14273\u2014Lowering drug prices by once again putting Americans first","first-page":"1","author":"Trump","year":"2025"},{"issue":"1","key":"10.1016\/j.hpopen.2026.100180_bb0030","first-page":"1","article-title":"The distortionary effects of government procurement: evidence from Medicaid prescription drug purchasing","volume":"121","author":"Duggan","year":"2006","journal-title":"Q J Econ"},{"key":"10.1016\/j.hpopen.2026.100180_bb0035","series-title":"American Economic Association Profiting from Most-Favored-Customer Procurement Rules","first-page":"166","volume":"15, no. 2","author":"Feng","year":"2023"},{"key":"10.1016\/j.hpopen.2026.100180_bb0040","series-title":"\u2018Savings from Most-Favored-nation (MFN) drug pricing policy\u2019, Washington DC","author":"Council of Economic Advisors","year":"2026"},{"key":"10.1016\/j.hpopen.2026.100180_bb0045","first-page":"1","article-title":"Most Favored nation drug pricing: aiming at pharma\u2019s Achilles heel","author":"Spatz","year":"2025","journal-title":"Health Affairs Forefront"},{"issue":"9","key":"10.1016\/j.hpopen.2026.100180_bb0050","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.jval.2025.06.010","article-title":"Referencing drug prices of other countries may not sustainably lower prices in the United States: lessons from Europe","volume":"28","author":"Grueger","year":"2025","journal-title":"Value Health"},{"key":"10.1016\/j.hpopen.2026.100180_bb0055","author":"Mulcahy"},{"key":"10.1016\/j.hpopen.2026.100180_bb0060","author":"Mulcahy"},{"issue":"7","key":"10.1016\/j.hpopen.2026.100180_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1002872","article-title":"Competition and price among brand-name drugs in the same class: a systematic review of the evidence","volume":"16","author":"Sarpatwari","year":"2019","journal-title":"PLoS Med"},{"issue":"7","key":"10.1016\/j.hpopen.2026.100180_bb0070","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-046917","article-title":"Determinants of drug prices: a systematic review of comparison studies","volume":"11","author":"Janssen Daalen","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.hpopen.2026.100180_bb0075","doi-asserted-by":"crossref","unstructured":"Ruggeri, K., Nolte, E. Pharmaceutical pricing: The use of external reference pricing. Santa Monica, CA: RAND Corporation, 2013. https:\/\/www.rand.org\/pubs\/research_reports\/RR240.html. Pages 1-58.","DOI":"10.7249\/rhq-03-02-06"},{"issue":"1","key":"10.1016\/j.hpopen.2026.100180_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40258-015-0182-5","article-title":"The end of the international reference pricing system?","volume":"14","author":"Persson","year":"2016","journal-title":"Appl Health Econ Health Policy"},{"issue":"6","key":"10.1016\/j.hpopen.2026.100180_bb0085","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/hec.1630","article-title":"External referencing and pharmaceutical price negotiation","volume":"20","author":"Garcia-Mari\u00f1oso","year":"2011","journal-title":"Health Econ"},{"issue":"2","key":"10.1016\/j.hpopen.2026.100180_bb0090","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s40258-018-0437-z","article-title":"Effectiveness of National Pricing Policies for patent-protected pharmaceuticals in the OECD: a systematic literature review","volume":"17","author":"Wettstein","year":"2019","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.hpopen.2026.100180_bb0095","article-title":"The risk of bias in non-randomized studies \u2013 of interventions (ROBINS-I) assessment tool","volume":"30","author":"Sterne","year":"2016","journal-title":"Accessed: Mar"},{"issue":"3","key":"10.1016\/j.hpopen.2026.100180_bb0100","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1162\/0033553041502144","article-title":"Market size in innovation: theory and evidence from the pharmaceutical industry","volume":"119","author":"Acemoglu","year":"2004","journal-title":"Q J Econ"},{"issue":"2","key":"10.1016\/j.hpopen.2026.100180_bb0105","article-title":"PRISMA2020: an R package and shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis","volume":"18","author":"Haddaway","year":"2022","journal-title":"Campbell Syst Rev"},{"issue":"11","key":"10.1016\/j.hpopen.2026.100180_bb0110","article-title":"Launch and Postlaunch Price developments of new drugs in the US","volume":"5","author":"Laube","year":"2024","journal-title":"Germany Switzerland JAMA Health Forum"},{"issue":"19","key":"10.1016\/j.hpopen.2026.100180_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph191912098","article-title":"Comparison of US and EU prices for orphan drugs in the perspective of the considered US orphan drugs act modifications and discussed Price-regulation mechanisms adjustments in US and European Union","volume":"19","author":"\u017belewski","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.hpopen.2026.100180_bb0120","first-page":"10","article-title":"Prescription drug prices in the US","volume":"319","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.hpopen.2026.100180_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3402\/jmahp.v4.32754","article-title":"A price comparison of recently launched proprietary pharmaceuticals in the UK and the US","volume":"4","author":"J\u00f8rgensen","year":"2016","journal-title":"J Mark Access Health Policy"},{"issue":"9","key":"10.1016\/j.hpopen.2026.100180_bb0130","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s40273-018-0667-9","article-title":"Estimating drug costs: how do manufacturer net prices compare with other common US Price references?","volume":"36","author":"Mattingly","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.hpopen.2026.100180_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.socscimed.2020.113042","article-title":"Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US","author":"Salas-Vega","year":"2020","journal-title":"Soc Sci Med"},{"issue":"4","key":"10.1016\/j.hpopen.2026.100180_bb0140","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1377\/hlthaff.2012.0920","article-title":"Higher us branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs","volume":"32","author":"Kanavos","year":"2013","journal-title":"Health Aff"},{"issue":"1","key":"10.1016\/j.hpopen.2026.100180_bb0145","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1377\/hlthaff.27.1.221","article-title":"International prices and availability of pharmaceuticals in 2005","volume":"27","author":"Danzon","year":"2008","journal-title":"Health Aff"},{"issue":"5","key":"10.1016\/j.hpopen.2026.100180_bb0150","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1377\/hlthaff.25.5.1353","article-title":"MarketWatch: prices and availability of biopharmaceuticals: an international comparison","volume":"25","author":"Danzon","year":"2006","journal-title":"Health Aff"},{"issue":"9","key":"10.1016\/j.hpopen.2026.100180_bb0155","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.healthpol.2018.07.005","article-title":"An analysis of expenditures on primary care prescription drugs in the United States versus ten comparable countries","volume":"122","author":"Morgan","year":"2018","journal-title":"Health Policy (New York)"},{"issue":"42","key":"10.1016\/j.hpopen.2026.100180_bb0160","doi-asserted-by":"crossref","first-page":"71548","DOI":"10.18632\/oncotarget.17742","article-title":"A global comparison of the cost of patented cancer drugs in relation to global differences in wealth","volume":"8","author":"Goldstein","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.hpopen.2026.100180_bb0165","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1524-4733.2007.00206.x","article-title":"Prices for innovative pharmaceutical products that provide health gain: a comparison between Australia and the United States","volume":"10","author":"Roughead","year":"2007","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.hpopen.2026.100180_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1002032","article-title":"Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis","volume":"13","author":"Iyengar","year":"2016","journal-title":"PLoS Med"},{"issue":"6","key":"10.1016\/j.hpopen.2026.100180_bb0175","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1017\/S104161020999086X","article-title":"International price comparisons of Alzheimer\u2019s drugs: a way to close the affordability gap","volume":"21","author":"Suh","year":"2009","journal-title":"Int Psychogeriatr"},{"issue":"3","key":"10.1016\/j.hpopen.2026.100180_bb0180","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1017\/S1744133111000090","article-title":"Determinants of branded prescription medicine prices in OECD countries","volume":"6","author":"Kanavos","year":"2011","journal-title":"Health Econ Policy Law"},{"key":"10.1016\/j.hpopen.2026.100180_bb0185","author":"Department of Health"},{"key":"10.1016\/j.hpopen.2026.100180_bb0190","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamainternmed.2022.4924","article-title":"Association between US drug Price and measures of efficacy for oncology drugs approved by the US Food and Drug Administration from 2015 to 2020","volume":"182","author":"Miljkovic","year":"2022","journal-title":"JAMA Intern Med"},{"issue":"5","key":"10.1016\/j.hpopen.2026.100180_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamanetworkopen.2019.4791","article-title":"Trends in prices of popular brand-name prescription drugs in the United States","volume":"2","author":"Wineinger","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.hpopen.2026.100180_bb0200","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S1470-2045(22)00073-0","article-title":"Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis","volume":"23","author":"Vokinger","year":"2022","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.hpopen.2026.100180_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/haschl\/qxaf051","article-title":"An analysis of US net cancer drug launch prices and clinical efficacy and certainty of evidence from 2008 to 2022","volume":"3","author":"Abuloha","year":"2025","journal-title":"Health Affairs Scholar"},{"issue":"9","key":"10.1016\/j.hpopen.2026.100180_bb0210","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1001\/jama.2020.1012","article-title":"Changes in list prices, net prices, and discounts for branded drugs in the US, 2007-2018","volume":"323","author":"Hernandez","year":"2020","journal-title":"JAMA - J American Med Associat"},{"issue":"12","key":"10.1016\/j.hpopen.2026.100180_bb0215","article-title":"Increasing divergence in drug prices between the United States","volume":"25","author":"Berkemeier","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.hpopen.2026.100180_bb0220","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/hec.2887","article-title":"The determinants of pricing in pharmaceuticals: are us prices really so high?","volume":"22","author":"Cabrales","year":"2013","journal-title":"Health Economics (United Kingdom)"},{"issue":"6","key":"10.1016\/j.hpopen.2026.100180_bb0225","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1200\/JOP.2016.014431","article-title":"Cancer drugs: an international comparison of Postlicensing Price inflation","volume":"13","author":"Savage","year":"2017","journal-title":"J Oncol Pract"},{"issue":"8","key":"10.1016\/j.hpopen.2026.100180_bb0230","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1002\/hec.4283","article-title":"Are drug prices subject to creative destruction? Evidence from the US, 1997\u20132017","volume":"30","author":"Lichtenberg","year":"2021","journal-title":"Health Economics (United Kingdom)"},{"issue":"4","key":"10.1016\/j.hpopen.2026.100180_bb0235","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1200\/JCO.2016.72.2124","article-title":"Trajectories of injectable cancer drug costs after launch in the United States","volume":"36","author":"Gordon","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hpopen.2026.100180_bb0240","series-title":"\u2018The life cycle of pharmaceuticals\u00a0: A cross-National Perspective\u2019, London","author":"Danzon","year":"2002"},{"issue":"4","key":"10.1016\/j.hpopen.2026.100180_bb0245","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1200\/JCO.2016.72.2124","article-title":"Trajectories of injectable cancer drug costs after launch in the United States","volume":"36","author":"Gordon","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hpopen.2026.100180_bb0250","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamainternmed.2022.4924","article-title":"Association between US drug Price and measures of efficacy for oncology drugs approved by the US Food and Drug Administration from 2015 to 2020","volume":"182","author":"Miljkovic","year":"2022","journal-title":"JAMA Intern Med"},{"issue":"4","key":"10.1016\/j.hpopen.2026.100180_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/haschl\/qxaf051","article-title":"An analysis of US net cancer drug launch prices and clinical efficacy and certainty of evidence from 2008 to 2022","volume":"3","author":"Abuloha","year":"2025","journal-title":"Health Affairs Scholar"},{"key":"10.1016\/j.hpopen.2026.100180_bb0260","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ahj.2018.08.006","article-title":"The relationship between pharmacy benefit managers (PBMs) and the cost of therapies in the US pharmaceutical market: a policy primer for clinicians","volume":"206","author":"Schulman","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.hpopen.2026.100180_bb0265","series-title":"Trump\u2019s cure for drug prices is worse than the disease.","author":"Donald","year":"2025"},{"issue":"5","key":"10.1016\/j.hpopen.2026.100180_bb0270","first-page":"403","article-title":"The role of pharmacy benefit managers and skyrocketing cost of medications","volume":"121","author":"Bollmeier","year":"2024","journal-title":"Mo Med"},{"key":"10.1016\/j.hpopen.2026.100180_bb0275","article-title":"The value of pharmacy benefit management","author":"Mulligan","year":"2022","journal-title":"SSRN Electron J"},{"issue":"3","key":"10.1016\/j.hpopen.2026.100180_bb0280","first-page":"4","article-title":"Comparing new prescription drug availability and launch timing in the United States and other OECD countries","volume":"11","author":"Mulcahy","year":"2024","journal-title":"RAND Health Care"},{"issue":"5","key":"10.1016\/j.hpopen.2026.100180_bb0285","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/hec.4004","article-title":"An empirical investigation of time-varying cost-effectiveness across the product life cycle","volume":"29","author":"Stevens","year":"2020","journal-title":"Health Economics (United Kingdom)"},{"key":"10.1016\/j.hpopen.2026.100180_bb0290","series-title":"Bargaining and International Reference Pricing in the Pharmaceutical Industry","author":"Dubois","year":"2022"},{"key":"10.1016\/j.hpopen.2026.100180_bb0295","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jhealeco.2014.04.003","article-title":"Regulation of pharmaceutical prices: evidence from a reference Price reform in Denmark","volume":"36","author":"Kaiser","year":"2014","journal-title":"J Health Econ"},{"issue":"2","key":"10.1016\/j.hpopen.2026.100180_bb0300","first-page":"34","article-title":"Impact of external Price referencing on medicine prices-a Price comparison among 14 European countries","volume":"5","author":"Leopold","year":"2012","journal-title":"South Med Rev"},{"issue":"1","key":"10.1016\/j.hpopen.2026.100180_bb0305","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1162\/rest.89.1.88","article-title":"Pharmaceutical Price controls and entry strategies","volume":"89","author":"Kyle","year":"2007","journal-title":"Rev Econ Stat"},{"issue":"2","key":"10.1016\/j.hpopen.2026.100180_bb0310","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1257\/mic.20210053","article-title":"Reference pricing as a deterrent to entry: evidence from the European pharmaceutical market","volume":"15","author":"Maini","year":"2023","journal-title":"Am Econ J Microecon"},{"issue":"5","key":"10.1016\/j.hpopen.2026.100180_bb0315","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1162\/rest_a_00849","article-title":"Does Medicare reimbursement drive up drug launch prices?","volume":"102","author":"Ridley","year":"2020","journal-title":"Rev Econ Stat"},{"key":"10.1016\/j.hpopen.2026.100180_bb0320","author":"IQVIA"},{"issue":"17","key":"10.1016\/j.hpopen.2026.100180_bb0325","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1001\/jama.2021.13338","article-title":"Estimated savings from international reference pricing for prescription drugs","volume":"326","author":"Mulcahy","year":"2021","journal-title":"JAMA - J American Med Associat"},{"key":"10.1016\/j.hpopen.2026.100180_bb0330","article-title":"European pharmaceutical Price regulation, firm profitability, and R&D spending","author":"Golec","year":"2006","journal-title":"SSRN Electron J"},{"key":"10.1016\/j.hpopen.2026.100180_bb0335","series-title":"Financial Effects of Pharmaceutical Price Regulation on R&D Spending by EU versus US Firms\u2019, Pharmacoeconomics","first-page":"1","volume":"vol. 28","author":"Golec","year":"2010"},{"issue":"1","key":"10.1016\/j.hpopen.2026.100180_bb0340","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1086\/426882","article-title":"Drug prices and research and development investment behavior in the pharmaceutical industry","volume":"48","author":"Giaccotto","year":"2005","journal-title":"J Law Econ"},{"issue":"2","key":"10.1016\/j.hpopen.2026.100180_bb0345","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40258-020-00601-9","article-title":"Revisiting the relationship between Price regulation and Pharmaceutical R&D Investment","volume":"19","author":"Shaikh","year":"2021","journal-title":"Appl Health Econ Health Policy"},{"issue":"5","key":"10.1016\/j.hpopen.2026.100180_bb0350","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.jhealeco.2011.07.005","article-title":"Regulatory policy and the location of bio-pharmaceutical foreign direct investment in Europe","volume":"30","author":"Koenig","year":"2011","journal-title":"J Health Econ"},{"issue":"1","key":"10.1016\/j.hpopen.2026.100180_bb0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hec.897","article-title":"Examining the link between price regulation and pharmaceutical R&D investment","volume":"14","author":"Vernon","year":"2005","journal-title":"Health Econ"},{"key":"10.1016\/j.hpopen.2026.100180_bb0360","author":"Garthwaite"},{"key":"10.1016\/j.hpopen.2026.100180_bb0365","article-title":"Pharmaceutical profits and the social value of innovation","volume":"no","author":"Dranove","year":"2014","journal-title":"NBER"},{"issue":"23","key":"10.1016\/j.hpopen.2026.100180_bb0370","first-page":"1","article-title":"Pharmaceutical regulation in Europe and its impact on corporate R&D","volume":"2011","author":"Eger","year":"2011","journal-title":"Heal Econ Rev"},{"issue":"1","key":"10.1016\/j.hpopen.2026.100180_bb0375","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jpubeco.2012.10.003","article-title":"Market size and innovation: effects of Medicare part D on pharmaceutical research and development","volume":"97","author":"Blume-Kohout","year":"2013","journal-title":"J Public Econ"},{"key":"10.1016\/j.hpopen.2026.100180_bb0380","author":"Klomp"},{"key":"10.1016\/j.hpopen.2026.100180_bb0385","series-title":"Health technology assessment in the U.S. \u2013 A vision for the future","author":"Lakdawalla","year":"2021"},{"key":"10.1016\/j.hpopen.2026.100180_bb0390","first-page":"1","article-title":"Can Trump really lower US drug prices and raise them in other countries? Probably not","volume":"no. June","author":"Dyer","year":"2025","journal-title":"Bmj"},{"issue":"10","key":"10.1016\/j.hpopen.2026.100180_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103726","article-title":"Analysis of pharma R&D productivity \u2013 a new perspective needed","volume":"28","author":"Schuhmacher","year":"2023","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.hpopen.2026.100180_bb0400","series-title":"Health at a glance 2023","author":"OECD","year":"2023"},{"key":"10.1016\/j.hpopen.2026.100180_bb0405","series-title":"Research and development in the pharmaceutical industry","author":"Congressional Budget Office","year":"2021"},{"issue":"2","key":"10.1016\/j.hpopen.2026.100180_bb0410","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40258-020-00601-9","article-title":"Revisiting the relationship between Price regulation and Pharmaceutical R&D Investment","volume":"19","author":"Shaikh","year":"2021","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.hpopen.2026.100180_bb0415","series-title":"Debunking value, access, and pricing myths: episode 2. Pricing in Germany is always transparent","volume":"12","author":"Cody","year":"2026"},{"issue":"2\u20133","key":"10.1016\/j.hpopen.2026.100180_bb0420","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1080\/17441056.2018.1512231","article-title":"Lower drug prices can improve innovation","volume":"14","author":"Canoy","year":"2018","journal-title":"European Competition J"},{"key":"10.1016\/j.hpopen.2026.100180_bb0425","series-title":"Health at a glance 2015. Paris","author":"OECD","year":"2015"},{"key":"10.1016\/j.hpopen.2026.100180_bb0430","article-title":"Drug discovery and development: introduction to the general public and patient groups","author":"Singh","year":"2023","journal-title":"Frontiers Media SA"},{"key":"10.1016\/j.hpopen.2026.100180_bb0435","author":"Kalindjian"},{"issue":"7","key":"10.1016\/j.hpopen.2026.100180_bb0440","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41571-018-0030-2","article-title":"Low-value approvals and high prices might incentivize ineffective drug development","volume":"15","author":"Prasad","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.hpopen.2026.100180_bb0445","series-title":"The future of European competitiveness\u2014A Competitiveness Strategy for Europe","author":"Draghi","year":"2024"}],"container-title":["Health Policy OPEN"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590229626000201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590229626000201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T09:40:44Z","timestamp":1793439644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590229626000201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":89,"alternative-id":["S2590229626000201"],"URL":"https:\/\/doi.org\/10.1016\/j.hpopen.2026.100180","relation":{},"ISSN":["2590-2296"],"issn-type":[{"value":"2590-2296","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of the United States most favored nation policies on prices of branded medicines and research and development","name":"articletitle","label":"Article Title"},{"value":"Health Policy OPEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hpopen.2026.100180","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100180"}}